However, these studies indicated that there were vaccine-elicited CD8+ T cells that could impact virus replication; although not sufficient enough to provide overall decreased risk of infection in the trial (either due to low magnitude/breadth/function of T cell responses and/or pre-existing vector immunity etc.). This evidence concerns the gene CD8A and infection.